The differential antibacterial and gastrointestinal effects of erythromycin and its chiral isolates

American Journal of Therapeutics

Volumn 13, Issue 1, 2006, Pages 48-56

  Cvetanovic, Ivana ^a   Ranade, Vasant ^a   Lin, Congrong ^a   Somberg, John ^a,b  

^a RUSH UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Antibiotic potency; Chirality; Erythromycin; Gastrointestinal contractility; Prokinetic agent

Indexed keywords

ERYTHROMYCIN;

ABDOMINAL DISCOMFORT; AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; COLON; CONTROLLED STUDY; DIARRHEA; DRUG POTENCY; ENTEROCOCCUS FAECALIS; GASTROINTESTINAL TRACT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS;

ACTION POTENTIALS; ANIMALS; ANTI-BACTERIAL AGENTS; COLON; ENTEROCOCCUS FAECALIS; ERYTHROMYCIN; MALE; MICROBIAL SENSITIVITY TESTS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 31544473778     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000155114.89092.96     Document Type: Article

References (36)

1. Brisson-Noël A, Trieu-Cuot P, Courvalis P. Mechanism of action of spiramycin and other macrolides. J Antimicrob Chemother. 1988;22(suppl B):13-23.
2. th ed. New York: McGraw-Hill; 1996:1123-1153.
3. Otterson MF, Sarna SK. Gastrointestinal motor effects of erythromycin. Am J Physiol. 1990;259:G355-G363.
4. Camilleri JF, Deharo JC, Panagides D, et al. Jet intravenous injection of erythromycin lactobionate. A possible cause of the occurrence crisis in torsade de pointe. Ann Cardiol Angiol. 1989;38:657-659.
5. Wayne A, Murray K, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-1096.
6. Tong KL, Lau YS, Teo WS. A case series of drug-induced long QT syndrome and torsade de pointes. Singapore Med J. 2001;42:566-570.
7. Tschida SJ, Guay DR, Straka RJ, et al. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy. 1996;6:663-674.
8. Zahger D, Gilon D, Gotsman MS. Delayed quinidine-induced diarrhea after five years of treatment. Chest. 1992;101:296.
9. Barker J, Christensen J. Some effects of quinidine and quinine on the electromyogram of the colon. Gastroenterology. 1973;65:773-777.
10. Gray VS. Syncopal episodes associated with cisapride and concurrent drugs. Ann Pharmacother. 1998;32:648-651.
11. Syed M, Tokuno H, Tomita T. Effects on cisapride in isolated guinea pig colon. Japan. J Pharmacol. 1989;51:47-56.
12. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45:371-377.
13. Farrely AM, Ro S, Callaghan BP, et al. Expression and function of KCNH2 (HERG) in the human jejunum. Am J Physiol Gastrointest Liver Physiol. 2003;284:G883-G895.
14. Poggioli R, Barreli A, Arletti R, et al. K channel openers delay intestinal transit and have antidiarrheal activity. Eur J Pharmacol. 1995;287:207-209.
15. Yaohui Z, Golden CM, Ye Y, et al. ERG K+ currents regulate pacemaker activity in ICC. Am J Physiol Gastrointest Liver Physiol. 2003;285:G1249-G1258.
16. Daleau P, Lessard E, Groleau MF, et al. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation. 1995;91:3010-3016.
17. Drici MD, Knollmann BC, Wang WX, et al. Cardiac actions of erythromycin: influence of female sex. JAMA. 1998;280:1774-1776.
18. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998;7:547-557.
19. Sarma SK, Soergel KH, Stone DH, et al. Gastrointestinal motor effects of erythromycin in humans. Gastroenterology. 1991;101:1488-1496.
20. Beesley TE, Scott RP. Chiral Chromatography. New York: John Wiley & Sons; 1998:173-219.
21. Tsuji K, Robertson JH. Determination of erythromycin and its derivatives by gas-liquid chromatography. Anal Chem. 1971;43:818-821.
22. Kuzel NR, Coffey HF. Technicon Symposium (1966), Vol. 2, Automation in Analytical Chemistry. White Plains, NY: Medical, Inc.; 1967:235-239.
23. Kuzel, Woodside JM, Comer JP, et al. Spectrophotometric determination of erythromycin in pharmaceutical products. Antibiotics and Chemotherapy. 1954:1234-1241.
24. Shuurkes JAJ, Van Nauten JM, Van Daele PGH, et al. Motor stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J Pharmacol Exp Ther. 1985;234:775-783.
25. The document addresses reference methods, broth microdilution, NCCLS. January 2000.
26. Calderon-Jaimes E, Arredondo-Garcia JL, Aguilar-Ituarte F, et al. In vitro antimicrobial susceptibility in clinical isolates of Enteroccocus species. Salua Publica Mex. 2003;45:96-101.
27. Hall JE, Harmer M. Erythromycin as a prokinetic agent in children. Anaesthesia. 1996;51:503-504.
28. Qin XY, Pilot MA, Thompson HH, et al. Comparison of the side effects and gastrointestinal mobility observed after administration of erythromycin josamycin to dogs. J Antimicrob Chemother. 1986;18:747-756.
29. Annese V, Janssens J, Vantrappen G, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology. 1992;102:823-828.
30. Annese V, Lombardi G, Frusciante V, et al. Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther. 1997;11:599-603.
31. Iannini P. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf. 2002;1:121-128.
32. Ohya S, Asakura K, Muraki K, et al. Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2002;282:G277-G287.
33. Shoeb F, Malykhina A, Akbarali H. Cloning and functional characterization of the smooth muscle Ether-a-go-go-related gene K+ channel. J Biol Chem. 2003;278:2503-2514.
34. Ishii K, Kondo K, Takahashi, et al. An amino acid residue whose change by mutation affects drug binding to the HERG channel. FEBS Lett. 2001;506:191-195.
35. Yeung CK, McCurrie JR, Wood D. Characterisation of the effects of potassium channel modulating agents on mouse intestinal smooth muscle. J Pharm Pharmacol. 2002;54:425-433.
36. Farkas A, Lepran I, Papp JG. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes. J Cardiovasc Pharmacol. 2002;39:287-297.